


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.52%
+0.01%
+104.79%
BIIB
Biogen
$164.80
Strengths

Earnings are forecast to grow

Trading below its fair value

Outperform the market
Chart
$143 (+15.24%)
$139.12 (+18.46%)
$127.31 (+29.45%)
$159.83 (+3.11%)
BIIB has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

BIIB overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
BIIB Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
BIIB Street Sentiment is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayAMGN
332.43
-1.29%
SCLX
17.76
-0.62%
CHRS
1.21
-3.97%
ALVO
5.55
+0.53%
What is BIIB current stock price?
What are BIIB stock strengths?
What risks are associated with BIIB stock?
When is BIIB next earnings report?
What is BIIB market cap and volume?
What is BIIB's current Stock IQ?
Should I buy BIIB stock right now?
Is BIIB a Strong Buy right now?
What does a 'Strong Buy' rating mean for BIIB?
What does a 'Strong Sell' rating mean for BIIB?
What factors influence BIIB's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-0.52%
+0.01%
+104.79%
BIIB
Biogen
Current Price
$164.80
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value

Outperform the market
Linked to BIIB
AMGN
332.43
-1.29%
SCLX
17.76
-0.62%
CHRS
1.21
-3.97%
ALVO
5.55
+0.53%

Chart
$143 (+15.24%)
$139.12 (+18.46%)
$127.31 (+29.45%)
$159.83 (+3.11%)
BIIB Analysts Opinion
BIIB Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
BIIB Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
BIIB Street Sentiment is bullish and have positive views on the near-term outlook
BIIB has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels.
BIIB Latest Analysis
Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript.
Thu Nov 13, 2025
What the Options Market Tells Us About Biogen. Investors with a lot of money to spend have taken a ish stance on BIIB).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals we don'.t know. But when something this big happens with BIIB it often means somebody knows something is about to happen.So how do we know what these investors just did?
Thu Nov 13, 2025
Biogen Inc. (BIIB) Presents at Wedbush Rewind ASN 2025 Conference Prepared Remarks Transcript.
Mon Nov 10, 2025
Stifel Upgrades Biogen (BIIB). Fintel reports that on November 6 2025 Stifel upgraded their outlook for Biogen (NasdaqGS:BIIB) from Hold to Buy. Analyst Price Forecast Suggests 11.61% Upside
Fri Nov 7, 2025
Stifel upgrades biotech stock on a narrative shift in Alzheimers treatment. Stifel sees Biogen stock rallying nearly 32% from here.
Thu Nov 6, 2025
Bernstein Maintains Biogen (BIIB) Market Perform Recommendation. Fintel reports that on November 3 2025 Bernstein maintained coverage of Biogen (NasdaqGS:BIIB) with a Market Perform recommendation. Analyst Price Forecast Suggests 15.57% Upside
Tue Nov 4, 2025
BIIB Beats on Q3 Earnings & Sales Stock Down on Lowered 25 EPS View. Biogens Q3 earnings and sales top estimates on strong drug demand but shares slide after the company cuts its 2025 EPS forecast.
Thu Oct 30, 2025
Biogen lowers 2025 EPS guidance despite Q3 beats.
Thu Oct 30, 2025
Biogen Non-GAAP EPS of $4.81 beats by $0.93 revenue of $2.54B beats by $200M.
Thu Oct 30, 2025
Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide. Biogen stock fell early Thursday after the biotech company cut its 2025 profit outlook due to an expected tax charge.The post Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide appeared first on Investor'.s Business Daily.
Thu Oct 30, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
BIIB Stock trends
BIIB Stock performance
BIIB Stock analysis
BIIB investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.